Japan-based Takeda readies strategic investment in Israel

Largest pharmaceutical company in Asia is now looking to fund promising seed companies that fit in with its strategic vision through its Silicon Valley-based venture fund.

By
May 12, 2015 18:34
2 minute read.
Takeda Pharmaceutical

Takeda Pharmaceutical Company HQ, in Chuo-ku, Osaka, Japan. (photo credit: Wikimedia Commons)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Japan-based Takeda Pharmaceuticals, the largest pharmaceutical company in Asia, is increasing efforts for strategic investments in Israel through Takeda Venture Investments (TVI), its Silicon Valley-based venture fund.

“I think there’s a unique set of conditions here in Israel that make it a great place for us to invest in innovation,” said Tetsuyuki Maruyama, who heads Takeda's research and development team in a Monday interview with The Jerusalem Post.

Be the first to know - Join our Facebook page.


In 2013, Takeda launched a commercial subsidiary in Israel to market its pharmaceutical products, and the following year it helped establish FutuRx, a biotech accelerator, with the help of OrbiMed Israel Partners and Johnson & Johnson Innovation.

Though four companies have gone through FutuRx, which focuses generally on biotech, Takeda is now looking to fund promising seed companies that fit in with its strategic vision through TVI. It is currently doing diligence on several promising prospects, according to Michal Silverberg, TVI's Senior Director of External Innovation, who is based in Israel.

According to Maruyama, the expansion in Israel is part of a recent change in the company's strategy, which pushed it toward more global engagement.

“Our external innovation strategy, or collaborative innovation strategy, is evolving rapidly in Takeda, and I think we’ve realized that in order to really succeed in a changing pharma market we have to look outside our walls to find innovations. And even outside the traditional places we work,” he said.

A decade ago, the company was comprised of almost all Japanese employees; now over two-thirds are international, and the company has commercial operations in 70 countries.

JPOST VIDEOS THAT MIGHT INTEREST YOU:


“In 2015 we are a very global company," Maruyama said. "As part of that we realized the opportunity to collaborate and tap into innovation in places we hadn’t before, so that was part of the drive to establish an R&D presence in Israel."

In particular, the company sees the future in greater personalization of medicine, but the vast technological upheavals going are pushing the company to keep looking in a variety of fields.

To that end, Maruyama has come to Israel to participate in the IATI Biomed conference, which in recent years has become one of the premier life sciences events in the world. “For me, it’s the most important one,” he said, adding that he generally skips other such conferences.

Indeed, according to the IVC Research Center, last year set an all-time record in investment in Israel's life sciences industry, with $801 million invested in 167 life sciences companies. That accounts for almost a quarter of all high-tech investments in Israel last year, the report said.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Money
November 18, 2018
Long-Term vs Short-Term Forex Trading Strategies

By JERUSALEM POST STAFF